NEW YORK (GenomeWeb) – CombiMatrix announced today that it has received conditional approval from the New York State Department of Health to market its CombiSNP chromosomal microarray analysis test for pediatric development disorders.

By gaining conditional approval, CombiMatrix will be able to market the test in New York while the assay is under Clinical Laboratory Reference System review. Upon completion of the review, either the test will receive full approval or additional information will be required in order to achieve final approval, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.